GlassScriptPhysician profile
Aleksandr M Kaplun
NPI 1508309709
$1,366.17
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.35 · 2022: $62.14 · 2024: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $137.30 | 2024 | Fasenra, Airsupra |
| Abbvie INC. | $99.23 | 2024 | |
| Lundbeck LLC | $98.66 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $88.21 | 2024 | Xarelto, Spravato |
| Ardelyx, INC. | $85.52 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $83.26 | 2024 | |
| Sumitomo Pharma America, INC. | $75.15 | 2024 | Gemtesa |
| Amgen INC. | $74.03 | 2024 | Prolia, Evenity |
| Scilex Pharmaceuticals INC. | $69.93 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.60 | 2024 | |
| Radius Health, INC. | $54.32 | 2024 | Tymlos |
| Pfizer INC. | $53.81 | 2024 | |
| Alkermes, INC. | $51.12 | 2022-2024 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.37 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $37.23 | 2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.14 | 2024 | Mounjaro, Zepbound |
| Smith+Nephew, INC. | $29.98 | 2024 | Collagenase Santyl |
| Glaxosmithkline, LLC. | $28.33 | 2024 | Trelegy Ellipta |
| Orexo US, INC. | $25.82 | 2022 | |
| Ironwood Pharmaceuticals, INC | $24.52 | 2024 | |
| Phathom Pharmaceuticals, INC. | $24.19 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $21.32 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $19.85 | 2024 | Gardasil, M-M-R II, Capvaxive |
| Novo Nordisk INC | $17.20 | 2024 | Wegovy |
| Kci USA, INC. | $16.35 | 2021 | |
| Indivior INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandr Kaplun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.